Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis (Q44908879)

7 December 2017

Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. (English)

1 reference

metabolic dysfunction–associated steatotic liver disease

7 December 2017

0 references

1 reference

11

Atsushi Nakajima

1 reference

7 December 2017

Sumio Watanabe

1

1 reference

7 December 2017

Etsuko Hashimoto

2

1 reference

7 December 2017

Kenichi Ikejima

3

1 reference

7 December 2017

Hirofumi Uto

4

1 reference

7 December 2017

Masafumi Ono

5

1 reference

7 December 2017

Yoshio Sumida

6

1 reference

7 December 2017

Masataka Seike

7

1 reference

7 December 2017

Yoshiyuki Takei

8

1 reference

7 December 2017

Tetsuo Takehara

9

1 reference

7 December 2017

Katsutoshi Tokushige

10

1 reference

7 December 2017

Masashi Yoneda

12

1 reference

7 December 2017

Toshiji Saibara

13

1 reference

7 December 2017

Goshi Shiota

14

1 reference

7 December 2017

Isao Sakaida

15

1 reference

7 December 2017

Makoto Nakamuta

16

1 reference

7 December 2017

Toshihiko Mizuta

17

1 reference

7 December 2017

Hirohito Tsubouchi

18

1 reference

7 December 2017

Kentaro Sugano

19

1 reference

7 December 2017

Tooru Shimosegawa

20

1 reference

7 December 2017

Japanese Society of Gastroenterology

21

1 reference

7 December 2017

Japan Society of Hepatology

22

1 reference

7 December 2017

24 February 2015

1 reference

Journal of Gastroenterology

7 December 2017

14

1 reference

based on heuristic

inferred from page(s)

published in

1 reference

7 December 2017

50

1 reference

7 December 2017

364-377

1 reference

7 December 2017

4

1 reference

Obesity and NASH in Japan

7 December 2017

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Prevalence of non-alcoholic fatty liver disease and its association with impaired glucose metabolism in Japanese adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

The metabolic syndrome as a predictor of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Systematic review: the epidemiology and natural history of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Prevalence and risk factors of nonalcoholic fatty liver disease in an adult population of taiwan: metabolic significance of nonalcoholic fatty liver disease in nonobese adults.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Increase in the prevalence of fatty liver in Japan over the past 12 years: analysis of clinical background

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

AGA technical review on nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

How should we manage patients with non-alcoholic fatty liver disease in 2007?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Prevalence and associated metabolic factors of nonalcoholic fatty liver disease in the general population from 2009 to 2010 in Japan: a multicenter large retrospective study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Prevalence of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis among a largely middle-aged population utilizing ultrasound and liver biopsy: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

GI epidemiology: nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Prevalence, gender, ethnic variations, and prognosis of NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Nonalcoholic steatohepatitis: cirrhosis, hepatocellular carcinoma, and burnt-out NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Etiology of liver cirrhosis in Japan: a nationwide survey

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Hepatocellular carcinoma in Japanese patients with nonalcoholic fatty liver disease, alcoholic liver disease, and chronic liver disease of unknown etiology: report of the nationwide survey.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Advances in pediatric nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Steatohepatitis: a tale of two "hits"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Genetic polymorphisms of the human PNPLA3 gene are strongly associated with severity of non-alcoholic fatty liver disease in Japanese

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Association of the rs738409 polymorphism in PNPLA3 with liver damage and the development of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Drugs and steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Clinical characteristics of de novo nonalcoholic fatty liver disease following pancreaticoduodenectomy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Endocrine and liver interaction: the role of endocrine pathways in NASH.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Association between serum TSH, free T4 and serum liver enzyme activities in a large cohort of unselected outpatients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Nonalcoholic fatty liver disease among patients with hypothalamic and pituitary dysfunction

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Systematic review: association of polycystic ovary syndrome with metabolic syndrome and non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Clinical and histologic spectrum of nonalcoholic fatty liver disease associated with normal ALT values

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Non-invasive markers associated with liver fibrosis in non-alcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

A simple clinical scoring system using ferritin, fasting insulin, and type IV collagen 7S for predicting steatohepatitis in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Noninvasive markers of fibrosis in nonalcoholic fatty liver disease: Validating the European Liver Fibrosis Panel and exploring simple markers

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

The utility of radiological imaging in nonalcoholic fatty liver disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Noninvasive assessment of liver fibrosis by measurement of stiffness in patients with nonalcoholic fatty liver disease (NAFLD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Nonalcoholic fatty liver disease: a spectrum of clinical and pathological severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Design and validation of a histological scoring system for nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Is weight reduction an effective therapy for nonalcoholic fatty liver? A systematic review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Randomized controlled trial testing the effects of weight loss on nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Comparison of weight-loss diets with different compositions of fat, protein, and carbohydrates

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

A 12-week aerobic exercise program reduces hepatic fat accumulation and insulin resistance in obese, Hispanic adolescents.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Aerobic exercise training reduces hepatic and visceral lipids in obese individuals without weight loss.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Randomized, placebo-controlled trial of pioglitazone in nondiabetic subjects with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

The role of thiazolidinediones in non-alcoholic steatohepatitis - a systematic review and meta analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Plasma transforming growth factor-beta1 level and efficacy of alpha-tocopherol in patients with non-alcoholic steatohepatitis: a pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Metformin in the treatment of patients with non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

The effect of metformin on leptin in obese patients with type 2 diabetes mellitus and nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Metformin in patients with non-alcoholic fatty liver disease: a randomized, controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Treatment with insulin sensitizer metformin improves arterial properties, metabolic parameters, and liver function in patients with nonalcoholic fatty liver disease: a randomized, placebo-controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Pharmacological Interventions for Nonalcoholic Fatty Liver Disease in Adults and in Children: A Systematic Review

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Meta-analysis: insulin sensitizers for the treatment of non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Ursodeoxycholic acid for treatment of nonalcoholic steatohepatitis: results of a randomized trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

High-dose ursodeoxycholic acid therapy for nonalcoholic steatohepatitis: a double-blind, randomized, placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Efficacy of atorvastatin for the treatment of nonalcoholic steatohepatitis with dyslipidemia

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

The fatty acid composition of plasma cholesteryl esters and estimated desaturase activities in patients with nonalcoholic fatty liver disease and the effect of long-term ezetimibe therapy on these levels

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Efficacy of ezetimibe for the treatment of non-alcoholic steatohepatitis: An open-label, pilot study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

NPC1L1 inhibitor ezetimibe is a reliable therapeutic agent for non-obese patients with nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Inhibitory effect of angiotensin II receptor antagonist on hepatic stellate cell activation in non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Angiotensin-receptor blockers as therapy for mild-to-moderate hypertension-associated non-alcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Pentoxifylline improves nonalcoholic steatohepatitis: a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Betaine for nonalcoholic fatty liver disease: results of a randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Outcome after liver transplantation for NASH cirrhosis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

The natural history of non-alcoholic fatty liver disease in children: a follow-up study for up to 20 years

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Iron overload is associated with hepatic oxidative damage to DNA in nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Effect of iron depletion in carbohydrate-intolerant patients with clinical evidence of nonalcoholic fatty liver disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Iron and insulin resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Iron depletion by phlebotomy improves insulin resistance in patients with nonalcoholic fatty liver disease and hyperferritinemia: evidence from a case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

The natural history of nonalcoholic fatty liver disease: a population-based cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Long-term follow-up of patients with NAFLD and elevated liver enzymes

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Long-term follow-up of patients with nonalcoholic fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Decreased survival of subjects with elevated liver function tests during a 28-year follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Risk of cancer in patients hospitalized with fatty liver: a Danish cohort study

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Non-alcoholic steatohepatitis: a common cause of progressive chronic liver injury?

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Nonalcoholic fatty liver disease and risk of future cardiovascular events among type 2 diabetic patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Nonalcoholic fatty liver disease is a novel predictor of cardiovascular disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Primary liver cancers with nonalcoholic steatohepatitis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Ethnic differences in the relationship between insulin sensitivity and insulin response: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Ala/Ala genotype of Pro12Ala polymorphism in the peroxisome proliferator-activated receptor-γ2 gene is associated with obesity and insulin resistance in Asian Indians

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

The Gly(972)Arg variant of human IRS1 gene is associated with variation in glomerular filtration rate likely through impaired insulin receptor signaling

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

The association of the triglyceride-to-HDL cholesterol ratio with insulin resistance in White European and South Asian men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

JSH Consensus Kobe 2009; Diagnosis and Treatment of NASH

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Transient elastography for measurement of liver stiffness measurement can detect early significant hepatic fibrosis in Japanese patients with viral and nonviral liver diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

Growth Hormone Reverses Nonalcoholic Steatohepatitis in a Patient With Adult Growth Hormone Deficiency

21 January 2018

1 reference

https://api.crossref.org/works/10.1007%2FS00535-015-1050-7

A position statement on NAFLD/NASH based on the EASL 2009 special conference

21 January 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25708290

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Pentoxifylline for the treatment of non-alcoholic steatohepatitis: a randomized controlled trial

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/25708290

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1007/S00535-015-1050-7

1 reference

7 December 2017

1 reference